A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
Phase 3
Completed
- Conditions
- Partial Seizures With or Without Secondary GeneralizationEpilepsy
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 449
- Registration Number
- NCT03083665
- Locations
- 🇨🇳
Ep0083 902, Guangzhou, China
🇨🇳Ep0083 912, Hangzhou, China
🇨🇳Ep0083 910, Shijiazhuang, China
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 49
- Registration Number
- NCT03025542
- Locations
- 🇦🇺
Ps0016 102, Kogarah, Australia
🇺🇸Ps0016 704, Bexley, Ohio, United States
🇦🇺Ps0016 101, Melbourne, Australia
A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
Phase 4
Completed
- Conditions
- Axial Spondyloarthritis (axSpA)Anterior Uveitis (AU)
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 89
- Registration Number
- NCT03020992
- Locations
- 🇵🇱
As0007 509, Poznań, Poland
🇨🇿As0007 103, Brno, Czechia
🇩🇪As0007 302, München, Germany
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 217
- Registration Number
- NCT03010527
- Locations
- 🇺🇸
Ps0011 709, Houston, Texas, United States
🇺🇸Ps0011 733, Dallas, Texas, United States
🇵🇱Ps0011 608, Krakow, Poland
Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 66
- Registration Number
- NCT02718716
- Locations
- 🇲🇩
Tp0001 601, Chisinau, Moldova, Republic of
🇧🇬Tp0001 1301, Sofia, Bulgaria
🇵🇱Tp0001 703, Gdańsk, Poland
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 42
- Registration Number
- NCT02625090
- Locations
- 🇧🇪
Ep0073 103, Brussels, Belgium
🇧🇬Ep0073 201, Sofia, Bulgaria
🇪🇸Ep0073 501, Sevilla, Spain
© Copyright 2025. All Rights Reserved by MedPath